Caldwell Sutter Capital, Inc. Brainstorm Cell Therapeutics Inc. Transaction History
Caldwell Sutter Capital, Inc.
- $202 Billion
- Q2 2024
A detailed history of Caldwell Sutter Capital, Inc. transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Caldwell Sutter Capital, Inc. holds 157,009 shares of BCLI stock, worth $34,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
157,009
Previous 157,009
-0.0%
Holding current value
$34,541
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding BCLI
# of Institutions
54Shares Held
12.3MCall Options Held
169KPut Options Held
30.6K-
Armistice Capital, LLC New York, NY7.92MShares$1.74 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$332,3400.0% of portfolio
-
Geode Capital Management, LLC Boston, MA484KShares$106,5420.0% of portfolio
-
Black Rock Inc. New York, NY386KShares$85,0110.0% of portfolio
-
Liberty Wealth Management LLC Oakland, CA340KShares$74,8330.02% of portfolio
About BRAINSTORM CELL THERAPEUTICS INC.
- Ticker BCLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,486,200
- Market Cap $8.03M
- Description
- Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...